Cost of integrating assisted partner services in HIV testing services in Kisumu and Homa Bay counties, Kenya: a microcosting study.


Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
14 Jan 2022
Historique:
received: 08 10 2021
accepted: 30 12 2021
entrez: 15 1 2022
pubmed: 16 1 2022
medline: 19 1 2022
Statut: epublish

Résumé

HIV assisted partner services (aPS), or provider notification and testing for sexual and injecting partners of people diagnosed with HIV, is shown to be safe, effective, and cost-effective and was scaled up within the national HIV testing services (HTS) program in Kenya in 2016. We estimated the costs of integrating aPS into routine HTS within an ongoing aPS scale-up project in western Kenya. We conducted microcosting using the payer perspective in 14 facilities offering aPS. Although aPS was offered to both males and females testing HIV-positive (index clients), we only collected data on female index clients and their male sex partners (MSP). We used activity-based costing to identify key aPS activities, inputs, resources, and estimated financial and economic costs of goods and services. We analyzed costs by start-up (August 2018), and recurrent costs one-year after aPS implementation (Kisumu: August 2019; Homa Bay: January 2020) and conducted time-and-motion observations of aPS activities. We estimated the incremental costs of aPS, average cost per MSP traced, tested, testing HIV-positive, and on antiretroviral therapy, cost shares, and costs disaggregated by facility. Overall, the number of MSPs traced, tested, testing HIV-positive, and on antiretroviral therapy was 1027, 869, 370, and 272 respectively. Average unit costs per MSP traced, tested, testing HIV-positive, and on antiretroviral therapy were $34.54, $42.50, $108.71 and $152.28, respectively, which varied by county and facility client volume. The weighted average incremental cost of integrating aPS was $7,485.97 per facility per year, with recurrent costs accounting for approximately 90% of costs. The largest cost drivers were personnel (49%) and transport (13%). Providers spent approximately 25% of the HTS visit obtaining MSP contact information (HIV-negative clients: 13 out of 54 min; HIV-positive clients: 20 out of 96 min), while the median time spent per MSP traced on phone and in-person was 6 min and 2.5 hours, respectively. Average facility costs will increase when integrating aPS to HTS with incremental costs largely driven by personnel and transport. Strategies to efficiently utilize healthcare personnel will be critical for effective, affordable, and sustainable aPS.

Sections du résumé

BACKGROUND BACKGROUND
HIV assisted partner services (aPS), or provider notification and testing for sexual and injecting partners of people diagnosed with HIV, is shown to be safe, effective, and cost-effective and was scaled up within the national HIV testing services (HTS) program in Kenya in 2016. We estimated the costs of integrating aPS into routine HTS within an ongoing aPS scale-up project in western Kenya.
METHODS METHODS
We conducted microcosting using the payer perspective in 14 facilities offering aPS. Although aPS was offered to both males and females testing HIV-positive (index clients), we only collected data on female index clients and their male sex partners (MSP). We used activity-based costing to identify key aPS activities, inputs, resources, and estimated financial and economic costs of goods and services. We analyzed costs by start-up (August 2018), and recurrent costs one-year after aPS implementation (Kisumu: August 2019; Homa Bay: January 2020) and conducted time-and-motion observations of aPS activities. We estimated the incremental costs of aPS, average cost per MSP traced, tested, testing HIV-positive, and on antiretroviral therapy, cost shares, and costs disaggregated by facility.
RESULTS RESULTS
Overall, the number of MSPs traced, tested, testing HIV-positive, and on antiretroviral therapy was 1027, 869, 370, and 272 respectively. Average unit costs per MSP traced, tested, testing HIV-positive, and on antiretroviral therapy were $34.54, $42.50, $108.71 and $152.28, respectively, which varied by county and facility client volume. The weighted average incremental cost of integrating aPS was $7,485.97 per facility per year, with recurrent costs accounting for approximately 90% of costs. The largest cost drivers were personnel (49%) and transport (13%). Providers spent approximately 25% of the HTS visit obtaining MSP contact information (HIV-negative clients: 13 out of 54 min; HIV-positive clients: 20 out of 96 min), while the median time spent per MSP traced on phone and in-person was 6 min and 2.5 hours, respectively.
CONCLUSION CONCLUSIONS
Average facility costs will increase when integrating aPS to HTS with incremental costs largely driven by personnel and transport. Strategies to efficiently utilize healthcare personnel will be critical for effective, affordable, and sustainable aPS.

Identifiants

pubmed: 35031037
doi: 10.1186/s12913-022-07479-4
pii: 10.1186/s12913-022-07479-4
pmc: PMC8759219
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

69

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

PLoS One. 2021 May 3;16(5):e0250434
pubmed: 33939722
Implement Sci. 2015 Feb 13;10:23
pubmed: 25884936
J Acquir Immune Defic Syndr. 2018 May 1;78(1):16-19
pubmed: 29406431
PLoS One. 2018 Jul 6;13(7):e0197305
pubmed: 29979704
AIDS Behav. 2017 Aug;21(8):2551-2560
pubmed: 28299518
AIDS. 2018 Jan 14;32(2):233-241
pubmed: 29135576
JMIR Res Protoc. 2021 May 20;10(5):e27262
pubmed: 34014172
Sex Transm Dis. 2016 Nov;43(11):690-695
pubmed: 27893598
PLoS Negl Trop Dis. 2008 Apr 30;2(4):e174
pubmed: 18446203
Health Policy Plan. 2014 Jan;29(1):115-26
pubmed: 23325584
AIDS Patient Care STDS. 2016 Nov;30(11):506-511
pubmed: 27849369
Diagnostics (Basel). 2020 May 19;10(5):
pubmed: 32438594
J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):437-42
pubmed: 22046601
Bull World Health Organ. 2014 Jul 1;92(7):499-511AD
pubmed: 25110375
BMC Health Serv Res. 2018 Sep 17;18(1):721
pubmed: 30223833
BMC Health Serv Res. 2017 Jul 11;17(Suppl 1):457
pubmed: 28722550
J Acquir Immune Defic Syndr. 2021 Jan 1;86(1):56-61
pubmed: 33044322
BMC Med. 2016 Feb 19;14:34
pubmed: 26891969
Sex Transm Dis. 2013 Dec;40(12):909-14
pubmed: 24220349
Health Policy Plan. 2017 Dec 1;32(10):1407-1416
pubmed: 29029086
EClinicalMedicine. 2020 May 22;22:100355
pubmed: 32490370

Auteurs

Beatrice Wamuti (B)

Department of Global Health, University of Washington, 325 9th Avenue, Box 359909, Seattle, WA, 98104, USA. bwamuti@uw.edu.

Monisha Sharma (M)

Department of Global Health, University of Washington, 325 9th Avenue, Box 359909, Seattle, WA, 98104, USA.

Edward Kariithi (E)

PATH- Kenya, Kisumu, Kenya.

Harison Lagat (H)

PATH- Kenya, Kisumu, Kenya.

George Otieno (G)

PATH- Kenya, Kisumu, Kenya.

Rose Bosire (R)

Kenya Medical Research Institute, Nairobi, Kenya.

Sarah Masyuko (S)

Department of Global Health, University of Washington, 325 9th Avenue, Box 359909, Seattle, WA, 98104, USA.
Ministry of Health, Nairobi, Kenya.

Mary Mugambi (M)

Ministry of Health, Nairobi, Kenya.

Bryan J Weiner (BJ)

Department of Global Health, University of Washington, 325 9th Avenue, Box 359909, Seattle, WA, 98104, USA.

David A Katz (DA)

Department of Global Health, University of Washington, 325 9th Avenue, Box 359909, Seattle, WA, 98104, USA.

Carey Farquhar (C)

Department of Global Health, University of Washington, 325 9th Avenue, Box 359909, Seattle, WA, 98104, USA.
Department of Epidemiology, University of Washington, Seattle, USA.
Department of Medicine, University of Washington, Seattle, USA.

Carol Levin (C)

Department of Global Health, University of Washington, 325 9th Avenue, Box 359909, Seattle, WA, 98104, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH